The Hi's and Lo's of Cytarabine in Acute Myeloid Leukemia.
Where this comes from
- Record sourced from PubMed, PMID 32284317.
- Also identified by DOI 10.1158/1078-0432.CCR-20-0462 and PMC identifier 9291266.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial. Using an intermediate dose of cytarabine, compared with conventional dose, was shown to improve disease-free and overall survival in adult patients in China up to age 55, particularly in patients with intermediate cytogenetic risk.<i>See related article by Wei et al., p. 3154</i>.
Medical subject headings
- Cytarabine
- Leukemia, Myeloid, Acute